Cytokinetics Grants Equity Awards to 29 New Employees Under Nasdaq Rules

Cytokinetics, Incorporated (CYTK) granted stock options to purchase 60,465 shares of common stock and 40,084 restricted stock units to 29 new employees. The equity incentive awards were made on October 15, 2026, as inducement grants for personnel who began employment at the cardiovascular biopharmaceutical company during September and October 2026.

The stock options carry an exercise price of $63.92 per share, matching the closing market price on the grant date, and have a ten-year term. The options vest over four years, with one-quarter vesting after one year and the remainder vesting monthly over the subsequent 36 months. The restricted stock units vest over a three-year schedule, with 40% vesting after the first year, another 40% after the second year, and the final 20% after the third year, subject to continued service. Shares of Cytokinetics were trading at $62.67, up 1.16% on the day.

Investors will look ahead to the fourth quarter of 2026, when the biopharmaceutical firm plans to submit a supplemental drug application for its cardiac muscle medication aficamten following positive Phase 3 trial results.